Catalyst Pharmaceuticals (CPRX) News Today $25.72 -0.02 (-0.08%) Closing price 04:00 PM EasternExtended Trading$25.78 +0.05 (+0.21%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - What's Next?Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 52-Week High - Here's WhyMarch 25 at 9:48 AM | marketbeat.comAdvantage Alpha Capital Partners LP Has $272,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Advantage Alpha Capital Partners LP lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 13,050 shares of the biopharmaceutical company's stock after selling 12,March 25 at 5:05 AM | marketbeat.comRaymond James Financial Inc. Invests $6.89 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Raymond James Financial Inc. acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 329,980 shares of the biopharmaceuticalMarch 24 at 3:15 AM | marketbeat.comZacks Research Has Negative Outlook of CPRX FY2025 EarningsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings estimates for Catalyst Pharmaceuticals in a research report issued on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceuticMarch 24 at 2:04 AM | marketbeat.comIntech Investment Management LLC Raises Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Intech Investment Management LLC raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 103.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,826 shares of the biopharmaceutical company's stoMarch 23 at 4:26 AM | marketbeat.comZacks Research Issues Positive Estimate for CPRX EarningsMarch 23 at 1:13 AM | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 1.9% - Here's WhyCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 1.9% - Here's WhyMarch 22 at 12:53 PM | marketbeat.comZacks Research Brokers Raise Earnings Estimates for CPRXCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research upped their Q1 2025 earnings estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceuticMarch 22 at 6:33 AM | marketbeat.comAdvisors Asset Management Inc. Has $3.47 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Advisors Asset Management Inc. cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 166,047 shares of the biopharmaceutical companyMarch 22 at 4:36 AM | marketbeat.comBrokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $32.50March 22 at 3:07 AM | americanbankingnews.comBoston Partners Purchases 16,601 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Boston Partners lifted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,291,868 shares of the biopharmaceutical company's stock after purchasing an additionalMarch 21, 2025 | marketbeat.comAmundi Has $1.29 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Amundi raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 188.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,609 shares of the biopharmaceutical company's stock after buyingMarch 19, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,246,925 shares ofMarch 18, 2025 | marketbeat.comRoyce & Associates LP Trims Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Royce & Associates LP lowered its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,864,351 shares of the biopharmaceutical companyMarch 17, 2025 | marketbeat.comVestcor Inc Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Vestcor Inc lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 53.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,865 shares of the biopharmaMarch 17, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by AnalystsShares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given an average rating of "Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has assigned a sMarch 17, 2025 | marketbeat.comUS Bancorp DE Has $130,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)US Bancorp DE decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 86.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,223 shares of the biopharmaceutical company's stock after selliMarch 17, 2025 | marketbeat.comGlobeflex Capital L P Has $4.07 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Globeflex Capital L P grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 319.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 194,786 shares of the biopharmaceutical company's stock after buying an additional 148,388 shares duriMarch 16, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Increased by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 74.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 731,900 shares of the biopharmacMarch 15, 2025 | marketbeat.comIs Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment?March 14, 2025 | insidermonkey.comTruist Financial Keeps Their Buy Rating on Catalyst Pharma (CPRX)March 14, 2025 | markets.businessinsider.comWealthfront Advisers LLC Invests $2.83 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Wealthfront Advisers LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,422 shares of the biopharmaceuticalMarch 14, 2025 | marketbeat.comJupiter Asset Management Ltd. Sells 217,957 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Jupiter Asset Management Ltd. reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 31.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 481,987 shares of the biopharmaceutical companMarch 13, 2025 | marketbeat.comCatalyst Pharmaceuticals: Undervalued Future With Multiple Upside CatalystsMarch 11, 2025 | seekingalpha.comProficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Proficio Capital Partners LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,258 shares of the biopharmaceutical cMarch 11, 2025 | marketbeat.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 44,904 Shares of StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 8, 2025 | marketbeat.comBrian Elsbernd Sells 62,975 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.March 6, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $1,447,165.50 in StockMarch 6, 2025 | insidertrades.comZooming In On Catalyst Pharmaceuticals' EarningsMarch 5, 2025 | uk.finance.yahoo.comClark Estates Inc. NY Has $3.88 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Clark Estates Inc. NY trimmed its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,743 shares of the biopharmaceuticalMarch 5, 2025 | marketbeat.comCatalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comCatalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa ChallengesMarch 3, 2025 | seekingalpha.comCatalyst Pharmaceuticals price target raised to $32 from $28 at BairdMarch 3, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $32.00 at Robert W. BairdRobert W. Baird upped their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday.March 3, 2025 | marketbeat.comOppenheimer & Co. Inc. Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Oppenheimer & Co. Inc. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 28.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,487 shares of the biopharmMarch 3, 2025 | marketbeat.comChase Investment Counsel Corp Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Chase Investment Counsel Corp bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 54,000 shares oMarch 2, 2025 | marketbeat.comY Intercept Hong Kong Ltd Purchases Shares of 27,836 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Y Intercept Hong Kong Ltd bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,836 shares of the biopharmaceutMarch 2, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.comStockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday.March 1, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday.March 1, 2025 | marketbeat.comCatalyst Pharmaceuticals Reports Record $491.7 Million in Total Revenues for Full Year 2024, Projects Continued Growth for 2025February 28, 2025 | nasdaq.comOversold Conditions For Catalyst Pharmaceuticals (CPRX)February 28, 2025 | nasdaq.comCatalyst Pharmaceuticals price target raised to $40 from $33 at StephensFebruary 28, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Up - Here's What HappenedCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Up - Here's WhyFebruary 28, 2025 | marketbeat.comCatalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at StephensStephens reiterated an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday.February 28, 2025 | marketbeat.comCatalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...February 28, 2025 | uk.finance.yahoo.comCatalyst Pharma (CPRX) Gets a Buy from Truist FinancialFebruary 28, 2025 | markets.businessinsider.comIeq Capital LLC Takes $313,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 15,013 shares of the biopharmaceutical company's stock, valued aFebruary 28, 2025 | marketbeat.comPrincipal Financial Group Inc. Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Principal Financial Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 600,488 shares of theFebruary 28, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Releases Earnings Results, Beats Expectations By $0.34 EPSCatalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.34. Catalyst Pharmaceuticals had a net margin of 31.01% and a return on equity of 40.79%.February 27, 2025 | marketbeat.comHere's What's Driving Catalyst Pharmaceuticals Stock 8% Higher TodayFebruary 27, 2025 | fool.com Remove Ads Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼1.070.62▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼186▲CPRX Articles Average Week Remove Ads Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDY News VTRS News ASND News PCVX News QGEN News ROIV News SRPT News RVMD News BBIO News LNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPRX Stock Free CPRX Stock Alerts